Turk Ilac ve Serum Sanayi AS (TRILC) - Total Assets
Based on the latest financial reports, Turk Ilac ve Serum Sanayi AS (TRILC) holds total assets worth TL6.12 Billion TRY (≈ $137.17 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See TRILC book value for net asset value and shareholders' equity analysis.
Turk Ilac ve Serum Sanayi AS - Total Assets Trend (2018–2024)
This chart illustrates how Turk Ilac ve Serum Sanayi AS's total assets have evolved over time, based on quarterly financial data.
Turk Ilac ve Serum Sanayi AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Turk Ilac ve Serum Sanayi AS's total assets of TL6.12 Billion consist of 52.1% current assets and 47.9% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 0.2% |
| Accounts Receivable | TL1.21 Billion | 30.2% |
| Inventory | TL431.63 Million | 10.8% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL6.45 Million | 0.2% |
| Goodwill | TL0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Turk Ilac ve Serum Sanayi AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Turk Ilac ve Serum Sanayi AS market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Turk Ilac ve Serum Sanayi AS's current assets represent 52.1% of total assets in 2024, an increase from 50.7% in 2018.
- Cash Position: Cash and equivalents constituted 0.2% of total assets in 2024, down from 3.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 30.2% of total assets.
Turk Ilac ve Serum Sanayi AS Competitors by Total Assets
Key competitors of Turk Ilac ve Serum Sanayi AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Turk Ilac ve Serum Sanayi AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.16 | 2.51 | 1.80 |
| Quick Ratio | 0.91 | 1.97 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL502.55 Million | TL1.21 Billion | TL151.61 Million |
Turk Ilac ve Serum Sanayi AS - Advanced Valuation Insights
This section examines the relationship between Turk Ilac ve Serum Sanayi AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 41.7% |
| Total Assets | TL3.99 Billion |
| Market Capitalization | $14.02 Million USD |
Valuation Analysis
Below Book Valuation: The market values Turk Ilac ve Serum Sanayi AS's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Turk Ilac ve Serum Sanayi AS's assets grew by 41.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Turk Ilac ve Serum Sanayi AS (2018–2024)
The table below shows the annual total assets of Turk Ilac ve Serum Sanayi AS from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | TL3.99 Billion ≈ $89.47 Million |
+41.69% |
| 2023-12-31 | TL2.82 Billion ≈ $63.14 Million |
+169.95% |
| 2022-12-31 | TL1.04 Billion ≈ $23.39 Million |
+68.57% |
| 2021-12-31 | TL619.53 Million ≈ $13.88 Million |
+55.22% |
| 2020-12-31 | TL399.12 Million ≈ $8.94 Million |
+49.42% |
| 2019-12-31 | TL267.12 Million ≈ $5.98 Million |
+40.70% |
| 2018-12-31 | TL189.85 Million ≈ $4.25 Million |
-- |
About Turk Ilac ve Serum Sanayi AS
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, capsules, ampoules, vials, ointments-creams, intravenous serums, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. Turk Ilac Ve Serum Sanayi Anonim Sirketi was founded in 2010 and is headquartered in Anka… Read more